Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease
Open Access
- 1 December 2018
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 10, 7013-7019
Abstract
Background: The optimal chemotherapy regimen for non-small-cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) remains unknown. Therefore, in this study, we investigated the real-world efficacy and safety of carboplatin (CBDCA) plus nab-paclitaxel (nab-PTX) as a first-line regimen for NSCLC patients with ILD. Patients and methods: We retrospectively reviewed advanced NSCLC patients with ILD who had received CBDCA plus nab-PTX as a first-line chemotherapy regimen between April 2013 and March 2018. Patients were diagnosed with ILD based on the findings of a pretreatment high-resolution computed tomography of the chest. Results: The 34 patients enrolled in this study were included in the efficacy and safety analysis. Collagen vascular disease or a history of exposure to dust or asbestos was not reported for any patients. The median age of patients was 71 years (range, 59–83 years), and 32 patients had a performance status of 0 or 1. The overall response rate was 38.2%. The median progression-free survival and overall survival were 5.8 months and 12.7 months, respectively. Chemotherapy-related acute exacerbation of ILD was observed in two patients (5.7%). Other toxicities were feasible, and no treatment-related deaths occurred. Conclusion: CBDCA plus nab-PTX, as a first-line chemotherapy regimen for NSCLC, showed favorable efficacy and safety in patients with preexisting ILD.Keywords
This publication has 34 references indexed in Scilit:
- Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot studyCancer Chemotherapy and Pharmacology, 2016
- Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study.2015
- The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung diseaseCancer Chemotherapy and Pharmacology, 2014
- Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.2012
- Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumoniaOncology Letters, 2012
- The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumoniasLung Cancer, 2011
- Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease.2010
- International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates risingInternational Journal of Cancer, 2005
- The epidemiology of interstitial lung disease and its association with lung cancerBritish Journal of Cancer, 2004
- Interstitial lung disease associated with drug therapyBritish Journal of Cancer, 2004